Interim Financial Report - 31 December 2024
Released
Released
Announcement PDF
Tetratherix Pty Ltd
ABN 72 607 771 077
Interim Financial Report - 31 December 2024
Tetratherix Pty Ltd
Contents
31 December 2024
Directors' report
Auditor's independence declaration
Consolidated statement of profit or loss and other comprehensive income
Consolidated statement of financial position
Consolidated statement of changes in equity
Consolidated statement of cash flows
Notes to the consolidated financial statements
Directors' declaration
Independent auditor's review report to the members of Tetratherix Pty Ltd
1
2
4
5
6
7
8
9
21
22
Tetratherix Pty Ltd
Directors' report
31 December 2024
The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as
the 'consolidated entity' or 'group') consisting of Tetratherix Pty Ltd (referred to hereafter as the 'company' or 'parent entity')
and the entities it controlled at the end of, or during, the half-year ended 31 December 2024.
Directors
The following persons were directors of Tetratherix Pty Ltd during the half-year and up to the date of this report, unless
otherwise stated:
Ali Fathi
David Harold Bottomley
William Anthony Knox
Gillian Shea (appointed 13 March 2025)
Emma Jane Cleary (appointed 13 March 2025)
Atlanta Daniel (appointed 10 April 2025)
Principal activities
Tetratherix is a biomedical company that has developed an advanced biomaterial platform called Tetramatrix, a proprietary
fluid matrix that induces minimal foreign body reaction. The principal activities include development programs in the areas of
regenerative medicine and commercialising medical device technology across multiple applications including Skeletal
Reconstruction, Surgical Spacing and Tissue Healing.
Dividends
There were no dividends paid, recommended or declared during the current or previous half-year.
Review of operations
The loss for the consolidated entity after providing for income tax amounted to $2,080,490 (31 December 2023: $1,332,242).
Significant changes in the state of affairs
There were no significant changes in the state of affairs of the consolidated entity during the half-year.
Matters subsequent to the end of the half-year
On 25 March 2025, the parent entity Tetratherix Pty Ltd changed its company name to Tetratherix Limited and became an
unlisted public company limited by shares (previously proprietary company limited by shares).
On 3 April 2025, Tetratherix BTX Pty Ltd (a wholly owned subsidiary of the parent entity) was incorporated.
No other matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect
the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in
future financial years.
Likely developments and results of operations
Notwithstanding the group's loss of $2,080,490 (31 December 2023: $1,332,242) and net liability of $8,420,810 (30 June
2024: $6,777,019), the annual report has been prepared on a going concern basis.
The group's ability to continue as a going concern is contingent upon additional capital raising activities. The company is
planning an Initial Public Offering (IPO), and given its past success from potential investors at the Non Deal Roadshow (NDR),
the directors are confident in securing the necessary funding. Whilst the directors are confident in securing the necessary
funding, there remains material uncertainty that may cast significant doubt on the group's ability to continue as a going
concern. Should the IPO not proceed as expected, the group may be required to seek alternative fundings sources or continue
other strategic options to continue as a going concern.
The group directors have considered this uncertainty and have prepared a comprehensive plan to manage the risk associated
with the IPO. A scenario was developed where capital raising was delayed until the end of Q3 FY2026 and still showed a
going concern position. This provides contingency to mitigate against potential delays with the IPO or alternate capital raising.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this directors' report.
2
Tetratherix Pty Ltd
Directors' report
31 December 2024
This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.
On behalf of the directors
___________________________
8 May 2025
3
To the Board of Directors of Tetratherix Pty Ltd
Auditor’s Independence Declaration under section 307C of the Corporations Act
2001
As lead auditor for the review of the financial statements of Tetratherix Pty Ltd for the half-year ended 31
December 2024, I declare that to the best of my knowledge and belief, there have been no contraventions of:
(a)
the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
(b)
any applicable code of professional conduct in relation to the review.
Yours sincerely,
Nexia Sydney Audit Pty Ltd
Erin Tanyag
Director
Date: 8 May 2025
4
Tetratherix Pty Ltd
Consolidated statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2024
Consolidated
31 December 31 December
Note
2024
2023
$
$
Revenue and other income
3
Total revenue and other income
Expenses
Employee benefits expense
Depreciation and amortisation expense
Product development expense
Administrative expense
Finance costs
Net fair value loss on financial liabilities
Total expenses
4
4
4
Loss before income tax expense
458,728
545,778
458,728
545,778
(1,167,476)
(33,334)
(151,257)
(724,096)
(40,720)
(422,335)
(2,539,218)
(676,458)
(32,073)
(380,803)
(715,306)
(73,380)
(1,878,020)
(2,080,490)
(1,332,242)
-
-
(2,080,490)
(1,332,242)
-
-
(2,080,490)
(1,332,242)
Cents
Cents
Income tax expense
Loss after income tax expense for the half-year
Other comprehensive income for the half-year, net of tax
Total comprehensive loss for the half-year
Earnings per share for loss
Basic earnings per share
Diluted earnings per share
27
27
(5,501)
(5,501)
(3,775)
(3,775)
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
5
Tetratherix Pty Ltd
Consolidated statement of financial position
As at 31 December 2024
Consolidated
31 December
30 June
Note
2024
2024
$
$
Assets
Current assets
Cash and cash equivalents
Trade and other receivables
Other assets
Total current assets
5
6
7
9,222,544
524,103
12,882
9,759,529
126,946
850,954
6,197
984,097
Non-current assets
Investments accounted for using the equity method
Property, plant and equipment
Right-of-use assets
Intangibles
Total non-current assets
10
8
9
11
329,008
152,229
15,238
496,475
236,634
168,835
16,040
421,509
10,256,004
1,405,606
Total assets
Liabilities
Current liabilities
Trade and other payables
Borrowings
Lease liabilities
Employee benefits
Preference shares
Convertible subscription notes
SAFE notes
Total current liabilities
12
13
14
15
16
17
18
349,746
4,950
45,653
181,759
5,709,203
7,317,869
2,969,681
16,578,861
266,574
4,950
38,732
122,756
5,709,203
6,142,215
Non-current liabilities
Borrowings
Lease liabilities
Employee benefits
Total non-current liabilities
13
14
15
1,799,067
196,616
102,270
2,097,953
1,769,748
222,004
48,658
2,040,410
Total liabilities
18,676,814
8,182,625
Net liabilities
(8,420,810)
(6,777,019)
3,983,860
208,359
(12,613,029)
2,610,970
1,144,550
(10,532,539)
(8,420,810)
(6,777,019)
Equity
Issued capital
Reserves
Accumulated losses
19
20
Total deficiency in equity
The above consolidated statement of financial position should be read in conjunction with the accompanying notes
6
Tetratherix Pty Ltd
Consolidated statement of changes in equity
For the half-year ended 31 December 2024
Total
Accumulated deficiency in
losses
equity
$
$
Consolidated
Issued
capital
$
Reserves
$
Balance at 1 July 2023
1,886,540
1,536,089
(7,978,563)
(4,555,934)
Loss after income tax expense for the half-year
Other comprehensive income for the half-year, net of tax
-
-
(1,332,242)
-
(1,332,242)
-
Total comprehensive loss for the half-year
-
-
(1,332,242)
(1,332,242)
178,828
-
164,304
-
178,828
164,304
Balance at 31 December 2023
2,065,368
1,700,393
(9,310,805)
(5,545,044)
Consolidated
Issued
capital
$
Reserves
$
Total
Accumulated deficiency in
equity
losses
$
$
Balance at 1 July 2024
2,610,970
1,144,549
(10,532,539)
(6,777,020)
Loss after income tax expense for the half-year
Other comprehensive income for the half-year, net of tax
-
-
(2,080,490)
-
(2,080,490)
-
Total comprehensive loss for the half-year
-
-
(2,080,490)
(2,080,490)
Transactions with owners in their capacity as owners:
Movement of reserves/issue of shares
Share based payments
1,372,890
-
(1,372,890)
436,700
-
436,700
Balance at 31 December 2024
3,983,860
208,359
(12,613,029)
(8,420,810)
Transactions with owners in their capacity as owners:
Contributions of equity, net of transaction costs
Share based payments
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes
7
Tetratherix Pty Ltd
Consolidated statement of cash flows
For the half-year ended 31 December 2024
Consolidated
31 December 31 December
2024
2023
$
$
Cash flows from operating activities
Receipts from customers (inclusive of GST)
Payments to suppliers (inclusive of GST)
(1,461,144)
37,352
(1,115,785)
Interest and other finance costs
Research and development grants
(1,461,144)
(11,401)
829,695
(1,078,433)
(65,667)
-
Net cash used in operating activities
(642,850)
(1,144,100)
Cash flows from investing activities
Payments for property, plant and equipment
Payments for intangibles
(108,300)
-
(19,991)
(8,000)
Net cash used in investing activities
(108,300)
(27,991)
Cash flows from financing activities
Proceeds from issue of shares
Proceeds from issue of convertible and SAFE notes
Repayment of borrowings
Repayment of lease liabilities
9,865,215
(18,467)
2,207,713
(332,357)
(18,000)
Net cash from financing activities
9,846,748
1,857,356
Net increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
9,095,598
126,946
685,265
260,575
Cash and cash equivalents at the end of the half-year
9,222,544
945,840
The above consolidated statement of cash flows should be read in conjunction with the accompanying notes
8
Tetratherix Pty Ltd
Notes to the consolidated financial statements
31 December 2024
Note 1. Material accounting policy information
General information
The financial statements cover Tetratherix Pty Ltd as a consolidated entity consisting of Tetratherix Pty Ltd and the entities it
controlled ("the consolidated entity" or "the group") for the half-year ended 31 December 2024. The financial statements are
presented in Australian dollars, which is Tetratherix Pty Ltd's functional and presentation currency.
Tetratherix Pty Ltd is a proprietary company limited by shares, incorporated and domiciled in Australia. Its registered office
and principal place of business are:
Registered office
Principal place of business
Suite 5307, Level 53
25 Martin Place
Sydney, 2000, NSW
Unit 29, 34-36 Ralph Street
Alexandria, NSW, 2015
A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report,
which is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of directors, on 8 May 2025. The directors
have the power to amend and reissue the financial statements.
These general purpose financial statements for the interim half-year reporting period ended 31 December 2024 have been
prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations
Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International
Financial Reporting Standard IAS 34 'Interim Financial Reporting'.
These general purpose financial statements do not include all the notes of the type normally included in annual financial
statements. Accordingly, these financial statements are to be read in conjunction with the consolidated entity's financial
statements for the year ended 30 June 2024.
The material accounting policies adopted are consistent with those of the previous financial year and corresponding interim
reporting period, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted
The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the
Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.
The adoption of these Accounting Standards and Interpretations did not have any material impact on the financial performance
or position of the Group during the half-year ended 31 December 2024.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
The amended Accounting Standards that are mandatory for the current reporting period and are relevant to the Group are set
out below.
AASB 2020-1 Amendments to Australian Accounting Standards Classification of Liabilities as Current or Non-Current and
AASB 2022-6 Amendments to Australian Accounting Standards - Non-current Liabilities with Covenants
AASB 2020-1 was issued in March 2020 and is applicable to annual periods beginning on or after 1 January 2024, as extended
by AASB 2020-6. Early adoption is permitted. AASB 2022-6 was issued in December 2022 and is applicable to annual periods
beginning on or after 1 January 2024. Early adoption is permitted where AASB 2020-1 is also early adopted.
9
Tetratherix Pty Ltd
Notes to the consolidated financial statements
31 December 2024
Note 1. Material accounting policy information (continued)
These standards amend AASB 101 Presentation of Financial Statements to clarify requirements for the presentation of
liabilities in the statement of financial position as current or non-current. The amendments clarify that a liability is classified as
non-current if an entity has the right at the end of the reporting period to defer settlement of the liability for at least 12 months
after the reporting period. If the deferral right is subject to the entity complying with covenants in the loan arrangement based
on information up to and including reporting date, the deferral right will exist where the entity is able to comply with the covenant
on or before the end of the reporting date even if compliance is assessed after the reporting date. The deferral right will be
deemed to exist at reporting date if the entity is required to comply with the covenant only after the reporting date based on
post-reporting date information. Additional disclosure is required about loan arrangements classified as non-current liabilities
in such circumstances which enables users of financial statements to understand the risk that the liabilities could become
repayable within twelve months after the reporting period. Classification of a liability as non-current is unaffected by the
likelihood that the entity will exercise its right to defer settlement of the liability for at least 12 months after the reporting date
or even if the entity settles the liability prior to issue of the financial statements. The meaning of settlement of a liability is also
clarified. These amendments do not have a material impact on the financial performance or position of the Group.
Going concern
The group has prepared the financial statements for half year ended 31 December 2024 on the going concern basis which
assumes normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.
For the half year ended 31 December 2024, the group incurred a loss of $ 2,080,490 (2023: loss of $ 1,332,242) and incurred
operating cash outflows of $642,850 (2023: operating cash outflows of $1,144,100). As at 31 December 2024, the group had
a net asset deficiency of $ 8,420,810 (30 June 2024: $6,777,019). These matters give rise to a material uncertainty that may
cast significant doubt on the group's ability to continue as a going concern.
Despite this, the Directors believe that the going concern assumption remains appropriate due to the following mitigating
factors:
The entity has $9.2m in cash and cash equivalents to ensure sufficient cash inflows to meet its obligations as they fall
due over the next 12 months after signing date of these financial statements.
The group is planning to undertake an Initial Public Offering (IPO) within the next 12 months, with a view of raising further
capital. The proceeds from the IPO are expected to strengthen the groups liquidity position and enable it to continue its
operations and achieve its business objectives. Should the IPO not proceed as expected, the group will be able to seek
alternative funding sources or continue other strategic options to continue as a going concern.
Ongoing R&D grants are expected based on the nature of business activities in the next 12 months.
Management has prepared a cash flow forecast for the next 12 months, considering expected capital and operational
inflows and outflows. Based on these forecasts, the group expects to have adequate resources to continue in operational
existence for beyond the next 12 months.
If the above plans do not come to fruition, then the company and group may not be able to continue as going concerns. In that
event, the carrying value of assets and liabilities may not be realised and settled at the amounts presented in the consolidated
statement of financial position.
Fair value measurement
Assets and liabilities measured at fair value are classified into three levels, using a fair value hierarchy that reflects the
significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers
between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value
measurement.
For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not
available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and
reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is
undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable,
with external sources of data.
Note 2. Operating segments
The company operates as a single operating segment, and its activities are not subdivided into different operating segments
for internal management purposes. Accordingly, the company does not prepare segmental financial information, as the
directors monitor the group as a whole.
10
Tetratherix Pty Ltd
Notes to the consolidated financial statements
31 December 2024
Note 3. Revenue and other income
Consolidated
31 December 31 December
2024
2023
$
$
Other income
Royalty income
Research and development grant income
458,728
33,956
511,822
Revenue and other income
458,728
545,778
Note 4. Expenses
Consolidated
31 December 31 December
2024
2023
$
$
Loss before income tax includes the following specific expenses:
Depreciation
Plant and equipment
Fixtures and fittings
Buildings right-of-use assets
13,288
2,638
16,606
12,728
2,739
16,606
Total depreciation
32,532
32,073
802
-
Total depreciation and amortisation
33,334
32,073
Finance costs
Interest and finance charges paid/payable on borrowings
Interest and finance charges paid/payable on lease liabilities
33,701
7,019
65,667
7,713
Finance costs expensed
40,720
73,380
Superannuation expense
Defined contribution superannuation expense
65,759
42,658
Share-based payments expense
Share-based payments expense
436,699
176,422
Employee benefits expense excluding superannuation
Employee benefits expense excluding superannuation
665,018
457,378
Amortisation
Other intangible asset
Note 5. Cash and cash equivalents
Consolidated
31 December
30 June
2024
2024
$
$
Current assets
Cash at bank
9,222,544
11
126,946
Tetratherix Pty Ltd
Notes to the consolidated financial statements
31 December 2024
Note 6. Trade and other receivables
Consolidated
31 December
30 June
2024
2024
$
$
Current assets
Other receivables
Government grant (R&D)
GST receivable
1,494
458,728
63,881
1,494
829,695
19,765
524,103
850,954
Note 7. Other assets
Consolidated
31 December
30 June
2024
2024
$
$
Current assets
Prepayments
12,882
6,197
Note 8. Property, plant and equipment
Consolidated
31 December
30 June
2024
2024
$
$
Non-current assets
Plant and equipment - at cost
Less: Accumulated depreciation
361,135
(210,885)
150,250
303,435
(197,597)
105,838
Fixtures and fittings - at cost
Less: Accumulated depreciation
212,830
(34,072)
178,758
162,230
(31,434)
130,796
Motor vehicles - at cost
Less: Accumulated depreciation
19,991
(19,991)
-
19,991
(19,991)
-
329,008
236,634
Reconciliations
Reconciliations of the written down values at the beginning and end of the current half-year are set out below:
Plant and
equipment
$
Consolidated
Fixtures and
fittings
$
Motor
vehicle
$
Total
$
Balance at 1 July 2024
Additions
Depreciation expense
105,838
57,700
(13,288)
130,796
50,600
(2,638)
-
236,634
108,300
(15,926)
Balance at 31 December 2024
150,250
178,758
-
329,008
12
Tetratherix Pty Ltd
Notes to the consolidated financial statements
31 December 2024
Note 9. Right-of-use assets
Consolidated
31 December
30 June
2024
2024
$
$
Non-current assets
Buildings - right-of-use assets
Less: Accumulated depreciation
332,134
(179,905)
332,134
(163,299)
152,229
168,835
The consolidated entity leases buildings for its offices located at Unit 29, 33 Ralph Street, Alexandria, for 5 years with an
option to renew for a further 5 years.
Reconciliations
Reconciliations of the written down values at the beginning and end of the current half-year are set out below:
Right-of-use
assets
$
Consolidated
Balance at 1 July 2024
Depreciation expense
168,835
(16,606)
Balance at 31 December 2024
152,229
Note 10. Investments accounted for using the equity method
Consolidated
31 December
30 June
2024
2024
$
$
Non-current assets
Investment in Tutelix
-
-
In January 2024, the Group entered into a Joint Venture (JV) with Koda Ventures Pty Ltd, each with 50% equity in the
company, Tutelix Pty Ltd (Tutelix). Tutelix is a start up company producing a biostealth hydrogel material. They are currently
awaiting TGA approval for distribution. The JV is accounted using the equity accounting method and had a nil carrying value
as at 31 December 2024 (30 June 2024: nil)
13
Tetratherix Pty Ltd
Notes to the consolidated financial statements
31 December 2024
Note 11. Intangibles
Consolidated
31 December
30 June
2024
2024
$
$
Non-current assets
Website - at cost
Less: Accumulated amortisation
Other intangible assets - at cost
Less: Accumulated amortisation
11,520
(11,520)
-
11,520
(11,520)
-
16,040
(802)
15,238
16,040
16,040
15,238
16,040
Reconciliations
Reconciliations of the written down values at the beginning and end of the current half-year are set out below:
Consolidated
Website
Other
intangibles
$
$
Total
$
Balance at 1 July 2024
Amortisation expense
-
16,040
(802)
16,040
(802)
Balance at 31 December 2024
-
15,238
15,238
Note 12. Trade and other payables
Consolidated
31 December
30 June
2024
2024
$
$
Current liabilities
Trade payables
Other payables
220,488
129,258
38,854
227,720
349,746
266,574
Note 13. Borrowings
Consolidated
31 December
30 June
2024
2024
$
$
Current liabilities
Loan - related parties
Non-current liabilities
Loan - NSW Medical Fund Device
14
4,950
4,950
1,799,067
1,769,748
1,804,017
1,774,698
Tetratherix Pty Ltd
Notes to the consolidated financial statements
31 December 2024
Note 13. Borrowings (continued)
NSW Medical Device Fund
The consolidated entity entered into a funding agreement with NSW Health Administration Corporation in October 2018. The
funding is to be used for the commercialisation of TrimphDent Medical Device.
The consolidated entity is not required to make any repayment of the loan until the project has achieved commercial success.
The applicable interest rate for the loan is calculated using the annual Consumer Price Index (CPI).
Note 14. Lease liabilities
Consolidated
31 December
30 June
2024
2024
$
$
Current liabilities
Lease liability
45,653
38,732
Non-current liabilities
Lease liability
196,616
222,004
242,269
260,736
Note 15. Employee benefits
Consolidated
31 December
30 June
2024
2024
$
$
Current liabilities
Annual leave
181,759
122,756
Non-current liabilities
Long service leave
102,270
48,658
284,029
171,414
Note 16. Preference shares
Consolidated
31 December
30 June
2024
2024
$
$
Current liabilities
Preference shares
5,709,203
5,709,203
Preference shares
Class A Preference Shares (Preference Shares) are Shares which essentially carry the same rights as Ordinary Shares.
Preference Shares can be converted to Ordinary Shares using a conversion price. There is no redemption option for the holder
of the Preference Shares and returns are in the form of dividends at the discretion of the group.
The Preference Shares are initially recognised at fair value, net of any transaction costs directly attributable to their issuance.
They are classified as financial liabilities in accordance with AASB 132 Financial Instruments: Presentation due to the antidilution clause resulting in the conversion rate to Ordinary Shares not being fixed. At IPO these preference shares will convert
to Ordinary Shares and be reclassified to equity. Any interest earned will be capitalised on conversion with no liability to the
company for this interest.
15
Tetratherix Pty Ltd
Notes to the consolidated financial statements
31 December 2024
Note 17. Convertible subscription notes
Consolidated
31 December
30 June
2024
2024
$
$
Current liabilities
Convertible notes
7,317,869
-
The convertible notes were issued with an option to convert into ordinary shares on redemption or the occurrence of a
conversion event (e.g. IPO). Each note accrues interest at a rate of 8.00% per annum. Interest is calculated on the face value
of the note and accrues daily until redemption or conversion. They are classified as financial liabilities in accordance with
AASB 132 Financial Instruments: Presentation due to the host contract at the option of the note holder being redeemable for
cash upon maturity or a default event; whilst the conversion feature will result in a variable number of ordinary shares being
issued in accordance with the conversion formula. At IPO these convertible notes will convert to Ordinary Shares and be
reclassified to equity. Any interest earned will be capitalised on conversion with no liability to the company for this interest.
The convertible notes are measured fair value through profit and loss as per AASB 9.
Note 18. SAFE notes
Consolidated
31 December
30 June
2024
2024
$
$
Current liabilities
SAFE notes
2,969,681
-
The company issued Simple Agreements for Future Equity (SAFE) notes, entitling the holders to convert their notes into Senior
Shares upon the occurrence of a qualifying financing event or upon a designated exit event and may redeem their notes for
cash or convert them into Senior Shares. They are classified as financial liabilities in accordance with AASB 132 Financial
Instruments: Presentation due to the host contract at the option of the note holder being redeemable for cash upon exit events,
whilst the conversion feature will result in a variable number of Senior Shares being issued in accordance with the conversion
formula. At IPO, the Directors expect the SAFE notes to convert to Ordinary Shares, which will result in a reclassification to
equity. The SAFE notes are measured fair value through profit and loss as per AASB 9.
Note 19. Issued capital
31 December
2024
Shares
Ordinary shares - fully paid
41,939
Consolidated
30 June
31 December
2024
2024
Shares
$
37,508
30 June
2024
$
3,983,860
2,610,970
Issue price
$
Movements in ordinary share capital
Details
Date
Shares
Balance
Issue of shares on exercise of options
Share premium on exercise of share options
1 July 2024
15 December 2024
15 December 2024
37,508
4,431
-
Balance
31 December 2024
41,939
16
$0.50
$309.34
2,610,970
2,215
1,370,675
3,983,860
Tetratherix Pty Ltd
Notes to the consolidated financial statements
31 December 2024
Note 19. Issued capital (continued)
Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion
to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company
does not have a limited amount of authorised capital.
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share
shall have one vote.
Capital risk management
The consolidated entity's objectives when managing capital is to safeguard its ability to continue as a going concern, so that
it can provide returns to shareholders and benefits for other stakeholders and to maintain an optimum capital structure to
reduce the cost of capital.
Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated
as total borrowings less cash and cash equivalents.
In order to maintain or adjust the capital structure, the consolidated entity may adjust the amount of dividend
Share your feedback
Discover